Physician profile
Steven G Spector
NPI 1619181674
$277,645.08
in general payments reported to CMS, 2019-2025
13 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $6,343 · 2021: $35K · 2022: $21K · 2023: $60K · 2024: $70K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $130K · Consulting Fee: $43K · Honoraria: $20K · Travel and Lodging: $13K · Food and Beverage: $8,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $129,808.00 |
| Consulting Fee | $43,057.00 |
| Honoraria | $20,251.00 |
| Travel and Lodging | $12,980.81 |
| Food and Beverage | $8,877.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95,965.98 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $93,300.74 | 2021-2025 | Spravato |
| Axsome Therapeutics, INC. | $59,974.04 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $21,279.76 | 2024-2025 | Cobenfy |
| Allergan, INC. | $6,585.74 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $147.18 | 2019-2025 | |
| Corium, LLC | $143.43 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.06 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $56.33 | 2019-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $32.17 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $31.10 | 2025 | Austedo Xr |
| Alkermes, INC. | $29.01 | 2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $14.54 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.